CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients with Relapsed or Refractory B-Cell non-Hodgkin Lymphomas By Ogkologos - July 16, 2026 59 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 10-year follow-up of a phase II study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength Could Functional Precision Medicine Be the New Precision Oncology? Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL MOST POPULAR ESMO Welcomes the WHO Global Status Report on Cancer with Key... July 15, 2026 Dad Is Making Baby Giggle, But When He Makes A Sheep... May 21, 2019 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Multiple... July 28, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Selinexor February 3, 2021 Load more HOT NEWS New on NCI’s Websites for October 2019 Doctors Worry Breast Cancer Cases Are Being Missed as Mammogram Rates... Cancer in Lymph Nodes May Help Tumors Spread by Enlisting Immune... Expanding Research on Dormant Cancer Cells Aims to Prevent Metastasis
